A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

Completed · Phase 1

Conditions studied: Healthy

In brief

The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy volunteers taking Renvela.

Key facts

Study ID

NCT02346890

Run by

Ardelyx

People needed

16

Starts

2013-04-01

Expected to finish

2013-04-01

Last updated by the study team

2015-01-27

Who can join

Age: 19 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy man or woman
• Body mass index between 18 and 29.9 kg/m2

You may not qualify if…

• Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (GI) tract
• Any surgery on the small intestine or colon, excluding appendectomy or cholecystectomy or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
• Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine, neurologic, psychiatric disease, or any condition that may interfere with the subject successfully completing the trial or that would present a safety risk to the subject.

Where it is running

• Healthcare Discoveries, LLC — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.